Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

SKYRIZI

RISANKIZUMAB-RZAA

Standard Dose
75MG/0.83ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview SKYRIZI is listed in Drugs@FDA under application 761105 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient RISANKIZUMAB-RZAA Form and strength INJECTABLE;INJECTION - 75MG/0.83ML Sponsor ABBVIE INC Submission history Latest submission status date: 2026-03-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview SKYRIZI is listed in Drugs@FDA under application 761105 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient RISANKIZUMAB-RZAA Form and strength INJECTABLE;INJECTION - 75MG/0.83ML Sponsor ABBVIE INC Submission history Latest submission status date: 2026-03-18 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.